Skip to main content
Equibles

Point72 Asset Management, L.P.

Position in TGTX — Tg Therapeutics, Inc.

CIK 1603466 STAMFORD, CT
Back to TGTX Full portfolio

Position in TGTX

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$14,557,067
+$7,660,286 QoQ
Shares Held
264,963
+14.5% QoQ
Ownership
0.173%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#60
of 426 holders
Holding Since
Sep 2022
10 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in TGTX Over Time

Shares Held

Position Value (USD)

Derivatives in TGTX

reported options exposure · as of Jun 30, 2026
CallValue
$5,263,252
CallShares
95,800
PutValue
$351,616
PutShares
6,400

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Point72 Asset Management, L.P. holds $2,243,273,342 across 172 Biotechnology names. TGTX ranks #42 (0.6% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ROIV
Roivant Sciences Ltd.
 4,473,478 $158,316,386
2 CYTK
Cytokinetics Inc
 1,587,712 $135,257,185
3 BBIO
BridgeBio Pharma, Inc.
 1,525,782 $113,640,243
4 AXSM
Axsome Therapeutics, Inc.
 416,516 $101,950,621
5 LEGN
Legend Biotech Corp
 3,076,124 $88,838,461
6 MDGL
Madrigal Pharmaceuticals, Inc.
 137,029 $73,577,721
7 CELC
Celcuity Inc.
 650,916 $68,098,831
8 ACAD
Acadia Pharmaceuticals Inc
 2,433,168 $61,559,150

All Filings in TGTX

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $351,616 6,400
2026-06-30 $14,557,067 264,963
2026-06-30 $5,263,252 95,800
2025-12-31 $6,896,781 231,358
2025-09-30 $13,215,681 365,832
2025-06-30 $25,823,184 717,510
2024-09-30 $2,339,000 100,000
2024-06-30 $10,422,680 585,873
2023-09-30 $5,113,628 611,678
2023-06-30 $7,905,826 318,270
2023-03-31 $311,042 20,681
2022-09-30 $2,588,224 437,200